We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Diabetes

Journal Scan / Review · June 19, 2021

High-Dose SGLT2 Inhibitors Are Better for Type 2 Diabetes

Diabetes, Obesity & Metabolism


Additional Info

Diabetes, Obesity & Metabolism
High-Dose Sodium-Glucose Co-Transporter 2 Inhibitors Are Superior in Type 2 Diabetes: A Meta-Analysis of Randomised Clinical Trials
Diabetes Obes Metab 2021 May 28;[EPub Ahead of Print], FH Shi, H Li, L Shen, JJ Fu, J Ma, ZC Gu, HW Lin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading